PTC Therapeutics
PTCT
148 hedge funds and large institutions have $1.15B invested in PTC Therapeutics in 2018 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 40 increasing their positions, 45 reducing their positions, and 18 closing their positions.
133% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 18
82% more capital invested
Capital invested by funds: $636M → $1.15B (+$519M)
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
18% more funds holding
Funds holding: 125 → 148 (+23)
10.26% more ownership
Funds ownership: 91.86% → 102.12% (+10%)
10% less call options, than puts
Call options by funds: $24.3M | Put options by funds: $27.1M
11% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 45
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$44.9M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$21.5M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$16.8M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$13.6M |
| 5 |
Morgan Stanley
New York
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
-$16M |
| 2 |
State Street
Boston,
Massachusetts
|
-$14.3M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$13.3M |
| 4 |
JGC
J. Goldman & Co
New York
|
-$10.9M |
| 5 |
SIM
Spark Investment Management
New York
|
-$9.67M |
PTCT Hedge Fund Activity: Q1 2018 in Review
148 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q1 2018, worth a combined $1.15B — up 82% from $636M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new PTCT positions and 18 closed out — a net gain of 24 holders — while 40 added to existing stakes and 45 trimmed.
The largest buyer was Scopia Capital Management, adding an estimated $44.9M. The largest seller was Parallax Volatility Advisers, exiting entirely with an estimated $16M sold.
- 148 institutional investors held PTC Therapeutics (PTCT) as of Q1 2018, up from 125 in Q4 2017.
- Funds reported $1.15B of PTC Therapeutics stock for Q1 2018, up 82% quarter-over-quarter.
- 42 funds opened new PTC Therapeutics positions in Q1 2018 and 18 closed out, a net change of +24 holders.
- The largest PTC Therapeutics buyer in Q1 2018 was Scopia Capital Management, an estimated $44.9M added.
- The largest PTC Therapeutics seller in Q1 2018 was Parallax Volatility Advisers, an estimated $16M sold.
Based on aggregated 13F filings for Q1 2018.